Trudell Medical Group Makes a Strategic Investment in Xenocor

Apollo Hospitals Saves 41 Yr Old Farmer Who Waited 91 Days for a Heart Transplant with Mitral Chip Implant

India's first two scientific papers on MitraClip have both been published from Apollo Hopsitals. Dr. Sai Satish is involved in the authorship of the APAC guidelines for MitraClip implants.

Append Medical Completes $7.4M Million Series A Round

Append Medical is a developer of the first no-implant minimally invasive solution for transcatheter Left Atrial Appendage (LAA) exclusion.  Today the company announced the...

Randomized Controlled Trial for the EkoSonic™ Endovascular System Commences

"Optimal treatment of PE is still poorly understood and there is a need for a coordinated institutional approach to this complex, life-threatening problem," said Kenneth Rosenfield, M.D., study co-lead principal investigator and section head, Vascular Medicine and Intervention, Division of Cardiology, Massachusetts General Hospital, Boston. "The lead investigators of the trial are pleased to collaborate with the PERT Consortium, which is committed to evidence-driven therapy and is proud to take part in the HI-PEITHO study, aiming to advance the care of patients with PE."

Xenocor Inc. today announced a strategic investment by Barvest Ventures Inc., a member company of the Trudell Medical Group, which is an innovator and global leader in respiratory care and medical device development.

Xenocor notes this investment will enable Xenocor to ramp up production and respond to growing demand for the Xenoscope™ — an FDA-approved, single-use, fog-free, portable, high-definition (HD) laparoscopic imaging system.

In addition, George Baran, Chair of the Trudell Medical Group will join the Xenocor board bringing years of market wisdom and insight in the areas of product development, production and global market distribution. Northgate Technologies Inc., a member company of Trudell Medical Group that designs and manufactures urology and minimally invasive surgical equipment, will be working closely with Xenocor to bring additional synergies to the relationship.

“Innovation has been critical for delivering solutions that improve quality of life and create positive economic outcomes. This has been our mission since our inception in 1922,” said George Baran, Chairman of the Trudell Medical Group. “We feel our investment in Xenocor is a continuation of this tradition and see every reason for the Xenoscope to be successfully introduced into many markets around the world.”

The Xenoscope

The Xenoscope offers both clinical and financial advantages that positively impact surgeons, staff, healthcare facilities and patients.  The technological innovations provide vastly improved image quality (HD and fog-free), eliminate cross-contamination, reduce arc patient burn injuries, minimize technical complications and operation room downtimes. The compact, portable design is a single cord plug-and-play unit, which makes it possible for easy integration and usage in multiple locations.  There are no large capital expenditures or expensive long-term maintenance contracts so the Xenoscope is readily accessible to markets of varying size.

“Not only is Trudell Medical Group a global leader in its product categories, but they also manufacture adjunct products that compliment our current offerings.  This strategic investment alliance is a win-win partnership, which leaves the door open to additional innovation,” said Evan Kelso, CEO of Xenocor. “We feel fortunate to have George Baran on the board and such a commanding ally as we move this product into broader availability.”   



Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.